Shilpa Medicare Q3 Profit Dips 18% On Exceptional Loss Despite Revenue Surge

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Shilpa Medicare Q3 Profit Dips 18% On Exceptional Loss Despite Revenue Surge
Overview

Shilpa Medicare reported a significant Q3 FY26 consolidated revenue surge of 28.3% YoY to ₹4,097 Cr. However, net profit fell 17.9% YoY to ₹608 Cr, primarily due to an exceptional loss of ₹12.86 Cr from gratuity liability adjustments. Standalone revenue also grew robustly by 32.1%, but standalone net profit remained flat amid exceptional items. The company did not provide forward-looking guidance.

📉 The Financial Deep Dive

Shilpa Medicare Limited's Q3 FY26 results revealed a stark divergence between top-line growth and bottom-line performance. Consolidated revenue for the quarter ended December 31, 2025, surged 28.3% year-on-year (YoY) to ₹4,097.27 Cr. This robust expansion, however, was significantly overshadowed by a 17.9% YoY decline in consolidated Net Profit attributable to owners of the Parent Company, which stood at ₹608.53 Cr.

The primary culprit behind this profit contraction was a substantial exceptional loss of ₹1,286.12 lakhs (approximately ₹12.86 Cr). This loss is attributed to adjustments in gratuity liability, necessitated by the implementation of new Labour Codes in India. Such one-off charges can distort the true operational performance of a business.

On a standalone basis, revenue from operations also demonstrated strong momentum, increasing by 32.1% YoY to ₹1,657.05 Cr. Yet, standalone Net Profit remained virtually flat, reported at ₹158.41 Cr, also impacted by exceptional items totalling ₹220.26 lakhs.

For the nine-month period ended December 31, 2025, consolidated revenue grew 15.2% YoY to ₹11,011.53 Cr, while consolidated Net Profit saw a decline of 6.9% YoY to ₹1,748.63 Cr. Standalone nine-month revenue increased by 11.9% YoY to ₹3,930.71 Cr, with Net Profit decreasing by 8.4% YoY to ₹673.66 Cr.

Earnings per share (EPS) figures reflect this trend. Standalone basic EPS for Q3 FY26 was ₹0.84 (adjusted for bonus shares, vs ₹5.26 in Q3 FY25), and consolidated basic EPS was ₹2.36 (adjusted for bonus shares, vs ₹10.56 in Q3 FY25).

The company also noted the completion of the merger of its wholly-owned subsidiary, INM Technologies Private Limited, with Shilpa Medicare, effective April 1, 2024, which led to restatements of prior period financial information and tax adjustments.

🚩 Risks & Outlook

The most significant risk highlighted is the impact of exceptional items on profitability. While revenue growth is a positive signal, the recurrence of such significant one-off charges could continue to suppress net profit. Investors will be keenly watching management's commentary in future calls to understand the permanency of these gratuity-related adjustments and the overall impact on future cost structures. The absence of forward-looking guidance from the company means the street will have to rely on its own estimates, making the next few quarters critical for assessing Shilpa Medicare's ability to translate strong sales into robust earnings growth.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.